首页> 外文期刊>Protein Expression and Purification >Expression, purification, and structural characterization of the bacteriorhodopsin-aspartyl transcarbamylase fusion protein.
【24h】

Expression, purification, and structural characterization of the bacteriorhodopsin-aspartyl transcarbamylase fusion protein.

机译:细菌视紫红质-天冬氨酰氨甲酰氨基甲酰酶融合蛋白的表达,纯化和结构表征。

获取原文
获取原文并翻译 | 示例
           

摘要

We are testing a strategy for creating three-dimensional crystals of integral membrane proteins which involves the addition of a large soluble domain to the membrane protein to provide crystallization contacts. As a test of this strategy we designed a fusion between the membrane protein bacteriorhodopsin (BR) and the catalytic subunit of aspartyl transcarbamylase from Escherichia coli. The fusion protein (designated BRAT) was initially expressed in E. coli at 51 mg/liter of culture, to yield active aspartyl transcarbamylase and an unfolded bacterio-opsin (BO) component. In Halobacterium salinarum, BRAT was expressed at a yield of 7 mg/liter of culture and formed a high-density purple membrane. The visible absorption properties of BRAT were indistinguishable from those of BR, demonstrating that the fusion with aspartyl transcarbamylase had no effect on BR structure. Electron microscopy of BRAT membrane sheets showed that the fusion protein was trimeric and organized in a two-dimensional crystalline lattice similar to that in the BR purple membrane. Following solubilization and size-exclusion purification in sodium dodecyl sulfate, the BO portion of the fusion was quantitatively refolded in tetradecyl maltoside (TDM). Ultracentrifugation demonstrated that BR and BRAT-TDM mixed micelles had molecular masses of 138 and 162 kDa, respectively, with a stoichiometry of one protein per micelle. High TDM concentrations (>20 mM) were required to maintain BRAT solubility, hindering three-dimensional crystallization trials. We have demonstrated that BR can functionally accommodate massive C-terminal fusions and that these fusions may be expressed in quantities required for structural investigation in H. salinarum. Copyright 1999 Academic Press.
机译:我们正在测试一种用于创建整体膜蛋白的三维晶体的策略,该策略涉及向膜蛋白添加大的可溶结构域以提供结晶接触。为了验证该策略,我们设计了膜蛋白细菌视紫红质(BR)与大肠杆菌天冬氨酰转氨甲酰酶催化亚基之间的融合体。融合蛋白(命名为BRAT)最初在大肠杆菌中以51 mg / L的培养量表达,以产生活性的天冬氨酰氨基甲酰转氨化酶和未折叠的细菌视蛋白(BO)组分。在盐杆菌中,BRAT以7 mg / L的培养量表达,并形成高密度的紫色膜。 BRAT的可见吸收特性与BR并无区别,表明与天冬氨酰转氨甲酰酶的融合对BR结构没有影响。 BRAT膜片的电子显微镜显示融合蛋白是三聚体,并组织成类似于BR紫色膜的二维晶格。在十二烷基硫酸钠中溶解并进行尺寸排阻纯化后,将融合部分的BO部分定量重新折叠在十四烷基麦芽糖苷(TDM)中。超速离心表明,BR和BRAT-TDM混合胶束的分子质量分别为138和162 kDa,每个胶束的化学计量为一种蛋白质。为了保持BRAT溶解度,需要高TDM浓度(> 20 mM),这阻碍了三维结晶试验。我们已经证明,BR可以在功能上适应大规模的C末端融合,并且这些融合可能以盐杆菌的结构研究所需的量表达。版权所有1999 Academic Press。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号